Osteoporosis, bone & mineral

Efficacy and Safety of Denosumab vs Zoledronic Acid in Osteogenesis Imperfecta (OI) Adults: A Prospective, Open-Label, Randomized Study

J Clin Endocrinol MetabPublished Randomised controlled trial

Authors' conclusion

Denosumab effectively increases aBMD in adults with OI, with similar efficacy to zoledronic acid. Long-term and large-sample studies are needed to confirm the antifracture efficacy and safety of denosumab in adult patients with OI.

Study context

Population
Adults with osteogenesis imperfecta (OI); 49 with identified pathogenic mutations
Participants
51 adults
Comparison
Denosumab vs zoledronic acid
  • Denosumabn = 25
  • Zoledronic acidn = 26reference
Primary endpoint
Percentage changes in aBMD, TBS and BTMs from baseline
Follow-up
6 and 12 months
Methodological detailsprospective, open-label
  • Prospective
  • Open-label

Primary result

As reported in the abstract

Percentage change in aBMD · 12 months
GroupLumbar spine areal bone mineral density (aBMD) changeTotal hip aBMD change
Denosumab4.34% (P = .005)1.45% (P = .023)
Zoledronic acid4.92% (P = .006)2.02% (P = .016)

Lumbar spine areal bone mineral density (aBMD) change

Denosumab4.34% (P = .005)
Zoledronic acid4.92% (P = .006)

Total hip aBMD change

Denosumab1.45% (P = .023)
Zoledronic acid2.02% (P = .016)

Further findings

OutcomeDenosumabZoledronic acid
Percentage change in TBS (increasing trend)1.39%2.70%
Trabecular bone score (TBS) change with denosumab by OI phenotype · 12 months · Milder phenotypes vs More severe phenotypes · significantly higher TBS increase with milder phenotypes
P = 0.030

BTMs after denosumab

Serum β-CTX and alkaline phosphatase markedly decreased after denosumab

Safety

Adverse events · study period

Denosumab had fewer adverse events than zoledronic acid

Original publication

Efficacy and Safety of Denosumab vs Zoledronic Acid in OI Adults: A Prospective, Open-Label, Randomized Study. J Clin Endocrinol Metab. Published 5 January 2024. doi:10.1210/clinem/dgae012

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.